Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation

被引：5

作者：

Zettl, Uwe Klaus ^{[1
,10
]}

Rommer, Paulus Stefan ^{[1
,2
]}

Aktas, Orhan ^{[3
]}

Wagner, Torsten ^{[4
]}

Richter, Joachim ^{[4
]}

Oschmann, Patrick ^{[5
]}

Cepek, Lukas ^{[6
]}

Elias-Hamp, Birte ^{[7
]}

Gehring, Klaus ^{[8
]}

Chan, Andrew ^{[9
]}

Hecker, Michael ^{[1
]}

机构：

[1] Rostock Univ, Med Ctr, Dept Neurol, Rostock, Germany

[2] Med Univ Vienna, Dept Neurol, Vienna, Austria

[3] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany

[4] Merck Healthcare Germany GmbH, Weiterstadt, Germany

[5] Bayreuth Hosp, Dept Neurol, Bayreuth, Germany

[6] Neurol Grp Practice, Ulm, Germany

[7] Neurol Private Practice, Hamburg, Germany

[8] Neuroctr Itzehoe, Itzehoe, Germany

[9] Univ Hosp Bern, Dept Neurol, Inselspital Bern, Bern, Switzerland

[10] Rostock Univ, Med Ctr, Dept Neurol, Div Neuroimmunol, Gehlsheimer Str 20, D-18147 Rostock, Germany

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2023年 / 19卷 / 11期

关键词：

Interferon beta-1a; multiple sclerosis; disease-modifying therapy; 25; years; generation; long-term efficacy; long-term safety; mechanisms of action; DISEASE-MODIFYING THERAPIES; MEMORY B-CELLS; RESOURCE UTILIZATION; GENE-EXPRESSION; DOUBLE-BLIND; IFN-BETA; ADHERENCE; MULTICENTER; TERM; ALEMTUZUMAB;

D O I：

10.1080/1744666X.2023.2248391

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

IntroductionInterferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment.Areas coveredBased on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the reference treatment, the use of IFN beta-1a sc across the patient life span and as a bridging therapy, recent data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc regarding vaccine responses.Expert opinionIFN beta-1a sc paved the way to effective immunomodulatory treatment of MS, enabled meaningful insights into the disease process, and remains a valid therapeutic option in selected vulnerable MS patient groups.

引用

页码：1343 / 1359

页数：17

共 192 条

[11] Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis [J].

Barzegar, Mahdi ;

Houshi, Shakiba ;

Sadeghi, Erfan ;

Hashemi, Mozhgan Sadat ;

Pishgahi, Ghasem ;

Bagherieh, Sara ;

Afshari-Safavi, Alireza ;

Mirmosayyeb, Omid ;

Shaygannejad, Vahid ;

Zabeti, Aram .

MULTIPLE SCLEROSIS INTERNATIONAL, 2022, 2022

[12] Autoantibodies neutralizing type I IFNs are present in ∼4% of uninfected individuals over 70 years old and account for ∼20% of COVID-19 deaths [J].

Bastard, Paul ;

Gervais, Adrian ;

Le Voyer, Tom ;

Rosain, Jeremie ;

Philippot, Quentin ;

Manry, Jeremy ;

Michailidis, Eleftherios ;

Hoffmann, Hans-Heinrich ;

Eto, Shohei ;

Garcia-Prat, Marina ;

Bizien, Lucy ;

Parra-Martinez, Alba ;

Yang, Rui ;

Haljasmagi, Liis ;

Migaud, Melanie ;

Sarekannu, Karita ;

Maslovskaja, Julia ;

de Prost, Nicolas ;

Tandjaoui-Lambiotte, Yacine ;

Luyt, Charles-Edouard ;

Amador-Borrero, Blanca ;

Gaudet, Alexandre ;

Poissy, Julien ;

Morel, Pascal ;

Richard, Pascale ;

Cognasse, Fabrice ;

Troya, Jesus ;

Trouillet-Assant, Sophie ;

Belot, Alexandre ;

Saker, Kahina ;

Garcon, Pierre ;

Riviere, Jacques G. ;

Lagier, Jean-Christophe ;

Gentile, Stephanie ;

Rosen, Lindsey B. ;

Shaw, Elana ;

Morio, Tomohiro ;

Tanaka, Junko ;

Dalmau, David ;

Tharaux, Pierre-Louis ;

Sene, Damien ;

Stepanian, Alain ;

Megarbane, Bruno ;

Triantafyllia, Vasiliki ;

Fekkar, Arnaud ;

Heath, James R. ;

Franco, Jose Luis ;

Anaya, Juan-Manuel ;

Sole-Violan, Jordi ;

Imberti, Luisa .

SCIENCE IMMUNOLOGY, 2021, 6 (62)

[13] Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a [J].

Battaglini, Marco ;

Vrenken, Hugo ;

Brocci, Riccardo Tappa ;

Gentile, Giordano ;

Luchetti, Ludovico ;

Versteeg, Adriaan ;

Freedman, Mark S. ;

Uitdehaag, Bernard M. J. ;

Kappos, Ludwig ;

Comi, Giancarlo ;

Seitzinger, Andrea ;

Jack, Dominic ;

Sormani, Maria Pia ;

Barkhof, Frederik ;

De Stefano, Nicola .

EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (07) :2024-2035

[14] Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage [J].

Baumhefner, Robert W. ;

Leng, Mei .

NEUROLOGY AND THERAPY, 2022, 11 (03) :1399-1408

[15] Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis - a review of population-specific evidence from randomized clinical trials [J].

Bayas, Antonios ;

Christ, Monika ;

Faissner, Simon ;

Klehmet, Juliane ;

Pul, Refik ;

Skripuletz, Thomas ;

Meuth, Sven G. .

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2023, 16

[16] Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study [J].

Bayas, Antonios ;

Ouallet, Jean Christophe ;

Kallmann, Boris ;

Hupperts, Raymond ;

Fulda, Ulrich ;

Marhardt, Kurt .

EXPERT OPINION ON DRUG DELIVERY, 2015, 12 (08) :1239-1250

[17] Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients [J].

Bianco, Assunta ;

Lucchini, Matteo ;

Totaro, Rocco ;

Fantozzi, Roberta ;

De Luca, Giovanna ;

Di Lemme, Sonia ;

Presicce, Giorgia ;

Evangelista, Luana ;

Di Tommaso, Valeria ;

Pastorino, Roberta ;

De Fino, Chiara ;

De Arcangelis, Valeria ;

Centonze, Diego ;

Mirabella, Massimiliano .

NEUROTHERAPEUTICS, 2021, 18 (04) :2598-2607

[18] Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications [J].

Bjornevik, Kjetil ;

Munz, Christian ;

Cohen, Jeffrey, I ;

Ascherio, Alberto .

NATURE REVIEWS NEUROLOGY, 2023, 19 (03) :160-171

[19] Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis [J].

Bjornevik, Kjetil ;

Cortese, Marianna ;

Healy, Brian C. ;

Kuhle, Jens ;

Mina, Michael J. ;

Leng, Yumei ;

Elledge, Stephen J. ;

Niebuhr, David W. ;

Scher, Ann, I ;

Munger, Kassandra L. ;

Ascherio, Alberto .

SCIENCE, 2022, 375 (6578) :296-+

[20] Interferons at age 50: past, current and future impact on biomedicine [J].

Borden, Ernest C. ;

Sen, Ganes C. ;

Uze, Gilles ;

Silverman, Robert H. ;

Ransohoff, Richard M. ;

Foster, Graham R. ;

Stark, George R. .

NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) :975-990

← 1 2 3 4 5 6 7 8 9 10 →